Management of Secondary Progressive Multiple Sclerosis: Prophylactic Treatment—Past, Present, and Future Aspects
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Management of Secondary Progressive Multiple Sclerosis: Prophylactic Treatment—Past, Present, and Future Aspects
Authors
Keywords
Secondary progressive multiple sclerosis, Interferon beta-1b, Interferon beta-1a, Mitoxantrone, Glucocorticosteroids, Azathioprine, Intravenous immunoglobulins, Cyclophosphamide, Masitinib, Daclizumab, Rituximab, Linomide, Treatment, Prophylactic treatment, Management
Journal
Current Treatment Options in Neurology
Volume 15, Issue 3, Pages 241-258
Publisher
Springer Nature
Online
2013-04-22
DOI
10.1007/s11940-013-0233-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study
- (2012) Patrick Vermersch et al. BMC Neurology
- Cortical lesions in multiple sclerosis: inflammation versus neurodegeneration
- (2012) H. Lassmann BRAIN
- Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality?
- (2012) Y. Simoni et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System
- (2012) Alexander Winkelmann et al. CURRENT PHARMACEUTICAL DESIGN
- Neurodegeneration in multiple sclerosis: novel treatment strategies
- (2012) Felix Luessi et al. Expert Review of Neurotherapeutics
- Evaluating the Potential Benefit of Interferon Treatment in Multiple Sclerosis
- (2012) Tobias Derfuss et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis
- (2012) Afsaneh Shirani et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study
- (2012) Peter Connick et al. LANCET NEUROLOGY
- Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
- (2012) Giancarlo Comi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis
- (2012) Benjamin M. Greenberg et al. JAMA Neurology
- Rituximab for Secondary Progressive Multiple Sclerosis
- (2011) Paulus S. Rommer et al. CNS DRUGS
- Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis
- (2011) Sarah Al-Izki et al. Multiple Sclerosis Journal
- A critical appraisal of treatment decisions in multiple sclerosis—old versus new
- (2011) Bernd C. Kieseier et al. Nature Reviews Neurology
- Follow-up study of MS patients treated with high-dose intravenous methylprednisolone
- (2010) S. T. F. M. Frequin et al. ACTA NEUROLOGICA SCANDINAVICA
- Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review
- (2010) James T Reston et al. Multiple Sclerosis Journal
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
- (2009) Kathleen Hawker et al. ANNALS OF NEUROLOGY
- The relation between inflammation and neurodegeneration in multiple sclerosis brains
- (2009) Josa M. Frischer et al. BRAIN
- Review: Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms
- (2009) Amer Awad et al. Therapeutic Advances in Neurological Disorders
- Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
- (2008) Amit Bar-Or et al. ANNALS OF NEUROLOGY
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started